The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 trial of the oncolytic virus SVV-001 with nivolumab and ipilimumab in patients with high-grade neuroendocrine neoplasms.
 
Chinmay Jani
No Relationships to Disclose
 
Isildinha Reis
No Relationships to Disclose
 
Rakhi Modak
No Relationships to Disclose
 
Daniel Cortes
No Relationships to Disclose
 
Stephanie Baboun
No Relationships to Disclose
 
Alexander Rivera
No Relationships to Disclose
 
Hung Trinh
Employment - Seneca Therapeutics
 
Paul Hallenbeck
Employment - Seneca Therapeutics
 
Dionysios Watson
No Relationships to Disclose
 
Samuel Kareff
Honoraria - Academy for Continued Healthcare Education; All Global Circle; Guidepoint Global; HealthCourse, Inc.; Integrity Continuing Education; M3 Health; Precisca; Research to Practice
Consulting or Advisory Role - Ipsen; Pathway MD; Regeneron
Speakers' Bureau - i3 Health
Travel, Accommodations, Expenses - FLASCO; IASLC
 
Jaime Merchan
Consulting or Advisory Role - Merck
Research Funding - Arcus Biosciences (Inst); BioNTech (Inst); Corvus Pharmaceuticals (Inst); DynamiCure Biotechnology (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); IMUGENE (Inst); Kalivir Immunotherapeutics (Inst); Merck (Inst); ModeX Therapeutics Inc (Inst); Peloton Therapeutics (Inst); Replimune (Inst); Rubius Therapeutics (Inst); Seattle Genetics/Astellas (Inst); Sillajen (Inst); Tizona Therapeutics, Inc. (Inst); Tocagen (Inst); Trishula Therapeutics (Inst); Tubulis GmbH (Inst); Vyriad (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
 
Gilberto Lopes
Stock and Other Ownership Interests - Biomab; CDR-Life; Immorta Bio; Lucence Diagnostics; Morphometrix; Xilis
Honoraria - AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Dr. Reddy's Laboratories; Janssen; Merck; Rigel
Consulting or Advisory Role - AstraZeneca; Coherus Biosciences; Dr. Reddy's Laboratories; Mirati Therapeutics; Pfizer; Regeneron
Research Funding - Abbvie (Inst); adaptimmune (Inst); AstraZeneca; AstraZeneca (Inst); Bavarian Nordic (Inst); Blueprint Medicines (Inst); BMS (Inst); E.R. Squibb Sons, LLC; EMD Serono (Inst); G1 Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Janssen (Inst); Lilly (Inst); Lucence; Lucence; Merck Sharp & Dohme (Inst); NOVARTIS (Inst); Pfizer (Inst); Rgenix (Inst); Roche (Inst); Tesaro (Inst); Xilis
Travel, Accommodations, Expenses - AstraZeneca; BeiGene; Boehringer Ingelheim; Celgene; Coherus Biosciences; Dr. Reddy's Laboratories; E.R. Squibb Sons, LLC; Ipsen; Janssen; Merck; Pfizer; Pharmacyclics; Seagen; Seagen
 
Peter Hosein
Consulting or Advisory Role - FibroGen; Revolution Medicines
 
Aman Chauhan
Stock and Other Ownership Interests - Elicio Therapeutics; immatics; Kura Oncology; MIST; Revolution Medicines
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Boehringer Ingelheim; Crinetics Pharmaceuticals; Curium Pharma; Exelixis; Sanofi/Aventis
Research Funding - Merck KGaA (Inst); NanoPharmaceuticals (Inst); Seneca Therapeutics (Inst)
Travel, Accommodations, Expenses - Entrinsic Health Solutions